GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » Pretax Margin %

XLO (Xilio Therapeutics) Pretax Margin % : -619.53% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Xilio Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was $-14.02 Mil. Xilio Therapeutics's Revenue for the three months ended in Sep. 2024 was $2.26 Mil. Therefore, Xilio Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was -619.53%.

The historical rank and industry rank for Xilio Therapeutics's Pretax Margin % or its related term are showing as below:

XLO' s Pretax Margin % Range Over the Past 10 Years
Min: -1359.37   Med: 0   Max: 0
Current: -1359.37


XLO's Pretax Margin % is ranked worse than
77.2% of 1013 companies
in the Biotechnology industry
Industry Median: -148.6 vs XLO: -1359.37

Xilio Therapeutics Pretax Margin % Historical Data

The historical data trend for Xilio Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilio Therapeutics Pretax Margin % Chart

Xilio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
- - - - -

Xilio Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -590.79 -619.53

Competitive Comparison of Xilio Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Xilio Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xilio Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Xilio Therapeutics's Pretax Margin % falls into.



Xilio Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Xilio Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-76.404/0
= %

Xilio Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-14.02/2.263
=-619.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xilio Therapeutics  (NAS:XLO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Xilio Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xilio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
828 Winter Street, Suite 300, Waltham, MA, USA, 02451
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Executives
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova officer: Chief Medical Officer C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield officer: Chief Operating Officer C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan officer: SVP, FINANCE AND ACCOUNTING C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English officer: Principal Accounting Officer 828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp 10 percent owner 71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p. 10 percent owner 101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105